跳转至内容
Merck
Home3D Cell CulturePatient-Derived Organoid Biobanks for Drug Discovery

Patient-Derived Organoid Biobanks for Drug Discovery

HUB Organoids BV is a pioneering biotechnology company specializing in the application of Organoid Technology to drug discovery, personalized medicine, and disease modeling. Founded in 2013 following the discovery of adult stem cells, the drug development platform from HUB uses advanced 3D organoid models derived from patient tissues, enabling more accurate and predictive research for preclinical testing and therapeutic development. This innovative platform accelerates the discovery of effective treatments by closely mimicking human biology and is available to scientists working in drug discovery and development in the therapeutic areas of oncology, inflammation and inflammatory bowel disease (IBD), infectious diseases, and toxicology investigations.

The words 'HUB Organoids' on top with 'is now part of Merck" on the bottom, centered.

Gastrointestinal Patient-Derived Organoids

Our extensive biobank of normal and diseased tissue-derived human gastrointestinal organoids includes over 50 highly characterized intestinal organoids derived from multiple regions of the digestive systems such as stomach, rectum, small intestine (duodenum, ileum), and colon. The biobank contains 58 patient samples of multiple ages and genders with high viability that were cultured in 3dGRO® L-WRN Conditioned Media.

Lung Patient-Derived Organoids

Our authenticated portfolio of human patient-derived lung cancer organoids includes adenocarcinoma and squamous cell carcinoma organoid lines. The 3dGRO® Human Lung Organoid biobank is derived from patient-derived xenograft, primary tumors, or metastatic patient tissues; the organoids express the major epithelial markers, adenocarcinoma markers, or squamous cell carcinoma markers.

Pancreatic Patient-Derived Organoids

We offer a 3dGRO® pancreatic organoid biobank for disease modeling research applications that consists of tissue-derived human pancreatic cancer organoids (PDAC organoids). Our biobank includes highly characterized organoid lines from PDAC diseased patients with primary tumors containing wild-type and KRAS driver mutations.

登录以继续。

如要继续阅读,请登录或创建帐户。

暂无帐户?